Neuroprotection
Since no FDA-approved therapy exists for TBI and TBI is second only to hemorrhage as a major combat injury, BTN brought together the Operation Brain Trauma Therapy (OBTT) consortium, comprised of military, academic and industry partners, to characterize the most promising therapies for TBI through valid and reproducible testing of neuroprotectants.
|
Aligning Clinical Practice Guidelines with Acute TBI Care
Hemorrhage is a leading cause of combat casualties and often occurs in conjunction with TBI. Clinical practice guidelines for hemorrhage may be contraindicated for TBI patients. BTN is researching, through preclinical TBI outcome testing, how such blood loss mitigation practices may be adjusted for more optimal care of complex injuries.
|